As global markets navigate the complexities of inflation data and interest rate speculations, Asian indices have shown resilience, with Japan’s stock markets reaching record highs and Chinese stocks advancing amid renewed trade negotiations. In such an environment, identifying undervalued stocks becomes crucial as investors seek opportunities that may offer potential growth despite broader economic uncertainties.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Xi’an NovaStar Tech (SZSE:301589) |
CN¥160.67 |
CN¥312.31 |
48.6% |
|
Sunjin Beauty ScienceLtd (KOSDAQ:A086710) |
₩10720.00 |
₩21037.18 |
49% |
|
SRE Holdings (TSE:2980) |
¥3115.00 |
¥6106.05 |
49% |
|
SK Biopharmaceuticals (KOSE:A326030) |
₩97200.00 |
₩189933.83 |
48.8% |
|
Matsuya R&DLtd (TSE:7317) |
¥717.00 |
¥1428.98 |
49.8% |
|
Lotes (TWSE:3533) |
NT$1350.00 |
NT$2686.73 |
49.8% |
|
Kolmar Korea (KOSE:A161890) |
₩79600.00 |
₩155807.48 |
48.9% |
|
Jiangxi Rimag Group (SEHK:2522) |
HK$19.16 |
HK$37.57 |
49% |
|
Fositek (TWSE:6805) |
NT$1060.00 |
NT$2092.67 |
49.3% |
|
EROAD (NZSE:ERD) |
NZ$2.35 |
NZ$4.63 |
49.2% |
Underneath we present a selection of stocks filtered out by our screen.
Overview: Dekon Food and Agriculture Group operates in the livestock and poultry breeding and farming sectors, with a market cap of HK$34.42 billion.
Operations: The company’s revenue is primarily derived from the sales of pigs (CN¥21.32 billion), poultry (CN¥3.07 billion), and ancillary products (CN¥6.12 billion).
Estimated Discount To Fair Value: 44.3%
Dekon Food and Agriculture Group is trading at HK$88.5, significantly below its estimated fair value of HK$159.01, suggesting it may be undervalued based on cash flows. Despite recent volatility in share price and a decline in net income for the first half of 2025, the company expects substantial profit growth due to improved management efficiency and reduced pig costs. Revenue growth is projected to outpace the Hong Kong market, reinforcing its value proposition.
Overview: InnoCare Pharma Limited is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for cancer and autoimmune diseases in China, with a market cap of HK$37.30 billion.
Operations: InnoCare Pharma Limited generates revenue by discovering, developing, and commercializing therapeutic drugs targeting cancer and autoimmune diseases within the Chinese market.
